- Home
- KPLT vs ANTX Comparison
KPLT vs ANTX Comparison
Compare KPLT & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- ANTX
- Stock Information
- Founded
- KPLT 2012
- ANTX 2017
- Country
- KPLT United States
- ANTX United States
- Employees
- KPLT N/A
- ANTX N/A
- Industry
- KPLT Diversified Commercial Services
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- KPLT Consumer Discretionary
- ANTX Health Care
- Exchange
- KPLT Nasdaq
- ANTX Nasdaq
- Market Cap
- KPLT 40.8M
- ANTX 37.6M
- IPO Year
- KPLT N/A
- ANTX 2022
- Fundamental
- Price
- KPLT $10.09
- ANTX $1.13
- Analyst Decision
- KPLT Hold
- ANTX Hold
- Analyst Count
- KPLT 2
- ANTX 5
- Target Price
- KPLT $12.00
- ANTX $3.50
- AVG Volume (30 Days)
- KPLT 19.0K
- ANTX 149.8K
- Earning Date
- KPLT 03-13-2025
- ANTX 03-27-2025
- Dividend Yield
- KPLT N/A
- ANTX N/A
- EPS Growth
- KPLT N/A
- ANTX N/A
- EPS
- KPLT N/A
- ANTX N/A
- Revenue
- KPLT $241,789,000.00
- ANTX N/A
- Revenue This Year
- KPLT $12.92
- ANTX N/A
- Revenue Next Year
- KPLT $6.23
- ANTX N/A
- P/E Ratio
- KPLT N/A
- ANTX N/A
- Revenue Growth
- KPLT 14.99
- ANTX N/A
- 52 Week Low
- KPLT $5.08
- ANTX $0.87
- 52 Week High
- KPLT $23.54
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- KPLT 59.27
- ANTX 44.20
- Support Level
- KPLT $9.00
- ANTX $1.09
- Resistance Level
- KPLT $11.76
- ANTX $1.20
- Average True Range (ATR)
- KPLT 0.68
- ANTX 0.05
- MACD
- KPLT 0.04
- ANTX 0.01
- Stochastic Oscillator
- KPLT 47.32
- ANTX 52.98
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.